Saturday 17 October 2026
Export RNAC’s income statement to Excel — free account
Cartesian Therapeutics, Inc.
RNAC Healthcare Biotechnology
Cartesian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 92.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.9%, EPS fell 7.84% and free cash flow fell 6.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.27
0.31
−4.71%
Follow RNAC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 4.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 4 | 2 | 5 | 4 | 4 | 5 | 3 | 2 | 4 |
P/S ratio |
66.95 | 7.95 | 3.91 | 1.50 | 4.38 | 13.17 | 16.18 | 287.43 | 1,009.46 | 22.42 |
Altman Z-Score |
(4.74) | (1.52) | (3.44) | (0.13) | (1.16) | (2.95) | (4.94) | (12.73) | (1.61) | 0.56 |
Altman Z″-Score (non-manufacturers) |
(10.08) | (2.96) | (8.32) | (0.94) | (5.83) | (7.62) | (10.37) | (29.46) | (4.44) | (1.09) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.97 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(10.57) | (44.19) | (4.36) | (14.04) | (11.84) | (42.25) | (8.41) | (4.67) | (16.50) | 122.25 |
Beneish M-Score |
8.92 | (3.09) | (1.43) | (0.25) | 1.73 | (3.23) | — | — | (4.11) | (4.01) |
P/B ratio |
0.00 | 0.00 | 0.00 | 1.77 | 16.53 | 0.00 | 12.90 | 0.00 | 4.03 | 3.30 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 1.77 | 16.53 | 0.00 | 12.90 | 0.00 | 4.03 | 3.30 |
EV/Sales |
30.80 | 3.11 | 1.87 | 0.52 | 3.17 | 8.31 | 8.70 | 312.53 | 666.54 | 13.49 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 3.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.17) | (5.10) | (0.95) | (1.83) | (4.47) | 5.54 | (1.13) | (1.09) | (2.65) | (5.52) |
EV/FCF |
(1.09) | (3.73) | (0.95) | (1.77) | (4.39) | 5.66 | (1.13) | (1.08) | (2.62) | (5.36) |
Quick Ratio |
8.45 | 9.29 | 1.26 | 5.76 | 1.91 | 1.79 | 2.72 | 1.06 | 8.81 | 6.16 |
Current Ratio |
8.65 | 9.43 | 1.33 | 5.91 | 2.00 | 1.86 | 2.77 | 1.20 | 8.99 | 6.33 |
Net Debt/EBITDA |
0.89 | 4.97 | 0.90 | (7.01) | 31.15 | 2.01 | 1.37 | 0.25 | 1.20 | 2.14 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 15.83% | 16.03% | 15.54% | 18.99% | 48.08% | 20.81% | 13.49% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.28 | 1.14 | (1.43) | 2.25 | (3.95) | 0.41 | 0.22 |
Asset Turnover |
0.01 | 0.11 | 0.11 | 0.68 | 0.52 | 0.13 | 0.09 | 0.01 | 0.00 | 0.12 |
Operating CF/Net income |
0.57 | 0.31 | 0.23 | (0.89) | 2.35 | (0.51) | 0.93 | 0.91 | 0.80 | 0.55 |
Capex/Depreciation |
(1.84) | (7.60) | (0.27) | (1.32) | (0.83) | (1.01) | 0.13 | (0.90) | (0.74) | (0.59) |
Interest Coverage |
— | — | (30.50) | 4.80 | (1.62) | (36.52) | (34.53) | (43.52) | (52.89) | (27.67) |
| 195.88% | 34.64% | 126.87% | 60.82% | (1,137.85%) | 1,433.57% | (3,716.01%) | (281.64%) | (122.36%) | 117.69% | |
| (35.63%) | (20.92%) | (93.31%) | 21.72% | (15.79%) | (51.98%) | (76.85%) | (89.76%) | (68.61%) | (54.81%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(102.99%) | (38.03%) | (891.93%) | 28.11% | (34.56%) | (96.75%) | (87.93%) | (721.23%) | (72.74%) | (48.18%) |
Average Days of Receivables |
145.50 | 8.18 | 124.24 | 32.15 | 42.53 | 158.87 | 273.33 | 0.00 | 111.09 | 9.71 |
Research and Development Expense of Revenue |
2,074.87% | 115.91% | 274.03% | 65.34% | 80.79% | 328.40% | 640.15% | 5,280.95% | 21,818.84% | 367.46% |
Selling, General and Administrative Expense of Revenue |
1,125.06% | 77.42% | 155.55% | 21.54% | 24.61% | 113.95% | 245.45% | 2,019.71% | 9,094.69% | 161.46% |
Intangible Assets out of Total Assets |
0.16 | 0.11 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
376.15% | 16.91% | 86.62% | 10.10% | 9.07% | 32.67% | 77.30% | 632.78% | 1,971.50% | 25.37% |
Graham Net Nets |
(1.57) | (0.73) | (3.48) | 0.46 | 0.02 | (0.10) | 0.05 | (0.13) | 0.24 | 0.29 |
Graham Number |
23.64 | 6.48 | 308.84 | 60.68 | 0.00 | 49.91 | 0.00 | 119.53 | 0.00 | 0.00 |
Earnings Yield |
(70.87%) | (26.45%) | (253.40%) | 24.37% | (7.37%) | (22.80%) | (51.31%) | (109.51%) | (31.38%) | (42.79%) |
Free Cash Flow Yield |
(42.40%) | (10.48%) | (50.56%) | (19.74%) | (16.51%) | 11.14% | (47.42%) | (100.75%) | (25.25%) | (11.23%) |
Revenue per Share |
0.11 | 2.25 | 5.03 | 22.98 | 22.35 | 4.92 | 4.40 | 1.21 | 0.30 | 23.13 |
Operating CF per Share |
(2.85) | (1.37) | (9.90) | (6.56) | (15.86) | 10.35 | (33.91) | (79.35) | (76.49) | (56.53) |
Capex per Share |
(0.21) | (0.51) | (0.04) | (0.25) | (0.28) | (0.22) | 0.05 | (1.05) | (1.07) | (1.67) |
Free Cash Flow per Share |
(3.06) | (1.88) | (9.93) | (6.81) | (16.15) | 10.13 | (33.86) | (80.40) | (77.56) | (58.20) |
Cash per Share |
4.82 | 12.31 | 14.88 | 27.92 | 33.64 | 41.15 | 59.45 | 50.17 | 142.07 | 240.97 |
Shareholders Equity per Share |
(4.86) | (0.39) | (27.01) | 19.46 | 5.92 | (5.34) | 5.54 | (7.27) | 76.17 | 157.24 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(4.86) | (0.39) | (27.01) | 19.46 | 5.92 | (5.34) | 5.54 | (7.27) | 76.17 | 157.24 |
Free Cash Flow |
(79.39) | (32.42) | (51.37) | (32.83) | (61.47) | 34.14 | (51.36) | (59.95) | (52.75) | (20.34) |
Working Capital |
114.34 | 193.65 | 22.52 | 123.06 | 72.19 | 69.80 | 61.72 | 6.93 | 87.71 | 73.11 |
Capital Expenditures |
(5.45) | (8.74) | (0.21) | (1.20) | (1.08) | (0.74) | 0.08 | (0.78) | (0.73) | (0.58) |
Net Current Asset Value |
(293.37) | (225.20) | (353.95) | 76.08 | 7.08 | (32.10) | 5.50 | (7.82) | 49.39 | 52.47 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 3.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.95 | 0.22 | 0.01 | 0.01 | 0.01 | 0.04 | (0.01) | 0.87 | 3.52 | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 11.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.24 | 0.12 | 0.36 | 0.33 | 0.61 | 0.53 | 0.47 | 0.41 | 0.47 | 0.49 |
Cash ROIC |
7,211.17% | (15.75%) | 81.90% | (12.89%) | (34.88%) | 23.32% | (43.72%) | (112.32%) | (31.12%) | (13.45%) |
Accounts Receivable Turnover |
2.82 | 8.00 | 2.79 | 11.26 | 9.93 | 2.72 | 2.64 | 0.00 | 1.49 | 15.56 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Receivables |
0.99 | 4.86 | 9.30 | 9.84 | 8.57 | 6.11 | 2.53 | — | 0.14 | 0.52 |
Average Payables |
0.79 | 1.72 | 1.73 | 0.27 | 0.33 | 0.47 | 0.80 | 1.35 | 2.74 | 3.03 |
Average Assets |
365.72 | 370.04 | 235.47 | 162.88 | 162.66 | 132.50 | 72.03 | 72.79 | 95.20 | 66.06 |
Average Common Equity |
(66.52) | (223.49) | (173.18) | 58.17 | 2.26 | (4.80) | 1.49 | 23.20 | 53.39 | (30.77) |
Columns are period end dates